Business Day (Johannesburg)
18 October 2007
Tests on GlaxoSmithKline's RTS,S candidate malaria vaccine show that it is safe and reduces infection in very young African babies, offering hope that a vaccine protecting children against the disease is within reach, scientists announced this week.
[ See Article ]
